Startup entity

Rusfertide

Product

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention JNJ-2113, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window.

Last mentioned: Jun 14, 2026

Entity pulse

Recent coverage · Rusfertide

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Rusfertide

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention JNJ-2113, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. Their average consequence score of 6 runs below the beat's 6.5 for that window. We currently track 1 Startup story that mention Rusfertide, all published on February 25, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Rusfertide. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Institutional Exit

    SEC filings reveal a $170 million position liquidation by a major fund.

  2. 120% Rally

    Stock price reaches a 12-month peak following sustained clinical momentum.

  3. J&J Partnership Expansion

    Johnson & Johnson expands the scope of the oral peptide collaboration.

  4. Phase 2 Success

    JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.

Stories mentioning Rusfertide 1

Market Trends Neutral

Protagonist Therapeutics Surges 120% as Major Fund Discloses $170M Exit

Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.

2 sources

Rusfertide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.